NYU Langone
J

Common TKI Toxicity Management in 2L HCC Treatment

By NYU Langone FEATURING Jennifer Wu
By NYU Langone FEATURING Jennifer Wu
420 views
May 4, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

13:36
Exelixis

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Feat. J. Gutierrez, J. Strauss

Featured Video

21:24
Exelixis

Hypothetical Patient Case: Hepatocellular Carcinoma with Progression…

Feat. J. Gutierrez, J. Strauss

Related Videos

17:12

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

1.6K views
18:21

GI Cancers: Hot Topics in 2024

Yale Cancer Center

J. Lacy

578 views
26:06

Perspectives on the Effects of Time Toxicity in Breast Cancer Treatm…

Kathryn Post

J. Hutchinson

657 views
20:09

ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunot…

2024 ESMO Annual Meeting Insights Hub

L. Rimassa

405 views
05:59

Oncologists' Perspectives on the Effects of Time Toxicity in Cancer …

Safiya Karim

358 views
15:19

Current Recommendations on Managing GI Adverse Reactions Associated …

Alberto Zambelli

952 views
32:47

Multidisciplinary Approach to Hepatocellular Carcinoma

UCLA Health

G. Choi, B. Yanny, S. Sadeghi, J. Hui

195 views
13:05

ESMO 2024 Summary: Highlights in HCC

2024 ESMO Annual Meeting Insights Hub

R. Kim, T. Biachi

222 views
20:41

Managing Dermatologic Toxicities: Cutaneous irAEs Associated with Im…

Cleveland Clinic Taussig Cancer Institute

R. Unwala

277 views
29:25

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

1.2K views
20:13

2024 Updates on Checkpoint Inhibitor Toxicities: A Nephrology Lens

Cleveland Clinic Taussig Cancer Institute

A. Mehdi

233 views
04:39

ESMO 2024 Insights: TACE ± Lenvatinib + Pembro for Int-Stage HCC - P…

2024 ESMO Annual Meeting Insights Hub

J. Llovet

210 views
14:27

Infectious Complications of Checkpoint Inhibitors: Discussing Overla…

Cleveland Clinic Taussig Cancer Institute

Z. Yetmar

217 views
14:28

ESMO 2024 Summary: Updates in HCC and Impacts on Practice

2024 ESMO Annual Meeting Insights Hub

H. Babiker

170 views
05:40

ESMO 2024 Insights: CheckMate 9DW Expanded Analysis - Nivo + Ipi vs.…

2024 ESMO Annual Meeting Insights Hub

H. Karachiwala

136 views
03:26

Expert Panel on TACE and TARE for HCC: Weighing the Pros and Cons

Integrity CE

M. Pishvaian, R. Salem

98 views
09:56

ESMO 2024 Insights: HIMALAYA - 5-Year OS of Tremelimumab + Durvaluma…

2024 ESMO Annual Meeting Insights Hub

L. Rimassa

173 views
28:57

Systemic Therapies for Melanoma and Immune Related Adverse Effects (…

Melanoma Research Foundation

S. Chandra

41 views
20:26

Choosing the Best HCC Treatment Based on Patient and Disease Stage

Integrity CE

M. Pishvaian, R. Finn, R. Salem, A. Singal

129 views
25:09

ASCO® 2024 Summary: "Experts Discuss Key Studies in HCC and BTC"

2024 ASCO® Annual Meeting Insights Hub

R. Kim, T. Biachi

380 views
AUTOPLAY